A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells
- 30 June 2010
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 46 (9), 1668-1678
- https://doi.org/10.1016/j.ejca.2010.02.017
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate CancerCancer Research, 2009
- The Anti-Cancer Activity of Noscapine: A ReviewRecent Patents on Anti-Cancer Drug Discovery, 2009
- Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient?Clinical Cancer Research, 2007
- Effective chemotherapy for hormone-refractory prostate cancer (HRPC): Present status and perspectives with taxane-based treatmentsCritical Reviews in Oncology/Hematology, 2007
- Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in miceMolecular Cancer Therapeutics, 2006
- Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell deathBiochemical Pharmacology, 2006
- Noscapine inhibits hypoxia-mediated HIF-1α expression andangiogenesis in vitro: a novel function for an old drugInternational Journal of Oncology, 2006
- Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivoThe Prostate, 2005
- Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cellsProceedings of the National Academy of Sciences of the United States of America, 1998
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990